Efficacy and Safety of Xinglou Chengqi Granule for Acute Ischemic Stroke
Opening soon Phase 2 NCT07163702
Run by Dongzhimen Hospital, Beijing · for 18 to 70 · All sexes
What this study is about
This is a Ⅱa clinical trial. The purpose of this study is to preliminarily explore the optimal dosage of Xinglou Chengqi Granules in the treatment of acute ischemic stroke and to evaluate the efficacy and safety of Xinglou Chengqi Granules for acute ischemic stroke.
Who can join (things the study team will check)
✅ You may be able to join if…
- Inpatients diagnosed with acute ischemic stroke.
- Meet the criteria of TCM phlegm-heat and fu-organ excess syndrome.
- Acute ischemic stroke within 7 days after onset.
- 6 ≤ NIHSS <20.
- Aged 18-70 years, male or female.
- The patient or representative has signed informed consent.
🚫 You may not be able to join if…
- Suspected secondary stroke caused by brain tumor, brain trauma, hemopathy, etc.
- NIHSS Ⅰa ≥2.
- Already dependent in activities of daily living before the present acute stroke (defined as modified Rankin Scare score ≥2 )
- Received or planned thrombolysis or endovascular therapy after onset.
- Known severe liver or kidney dysfunction (alanine aminotransferase or aspartate transaminase > 2.5 times the upper limit of normal value, serum creatinine > 1.5 times the upper limit of normal value)
- With cancers or uncontrolled diabetes.
- The expected survival time is less than 3 months.
- Patients who have used other traditional Chinese medicine for treating acute ischemic stroke since stroke onset.
- Patients with severe mental disorders, dementia, or other comorbid diseases that may affect neurological function examination.
- With a history of alcohol or drug abuse or drug dependence.
- Those known to be allergic to the investigated drug or its components.
- Pregnancy, potential pregnancy, or breastfeeding.
- Currently participating in other clinical trials during the past 3 months.
- Those who are judged by researchers to have poor compliance or are not suitable for participating in this study for any other reason.
Where this trial is running
- Dongzhimen Hospital, Beijing University of Chinese Medicine, Richmond, British Columbia, Canada
Who to contact
Xinxing Lai, M.D. · +8615901111280 · new-star@163.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07163702.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.